Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115078 | 0.95 | GSK3B (0.66) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL2602769 | 0.95 | GSK3B (0.66) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL2115071 | 0.95 | GSK3B (0.66) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL2114659 | 0.93 | GSK3B (0.62) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722266 | 0.88 | GSK3B (0.83) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL2116576 | 0.87 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL2115261 | 0.87 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13721953 | 0.87 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL4027349 | 0.87 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722127 | 0.87 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| EP-2193129-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009035162-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | GSK3B 972/4885CYP2D6 25/4885CYP1A2 71/4885 |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | GSK3B 562/4885CYP2D6 3712/4885CYP1A2 4207/4885 |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | GSK3B 562/4885CYP2D6 3712/4885CYP1A2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.